Is TransMedics Group (TMDX) overvalued or fairly valued?

MarketChacha shows TransMedics Group's valuation in context — a trailing P/E of about 33.8, a forward P/E of about 32.8, a price-to-book of about 4.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does TransMedics Group's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.14×) from reported figures — education, not a rating.

What is TransMedics Group's revenue?

TransMedics Group reported revenue of $605.5M for FY2025, with net profit of $190.3M, per official filings.

What is the share price of TransMedics Group (TMDX)?

TransMedics Group last traded at $74.01 (+3.4% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

TransMedics Group

TMDX · NYSE · Healthcare · United States

Snapshot

TickerTMDX

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees898

HeadquartersAndover, United States

Websitewww.transmedics.com

Filings tracked16

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Who owns it

Insiders3.6%
Institutions96.4%
Public & other0.0%

492 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.19%
FMR, LLC14.85%
Vanguard Portfolio Management LLC5.60%
Vanguard Capital Management LLC4.33%
State Street Corporation4.11%
Nomura Asset Management International Inc2.63%
Geode Capital Management, LLC2.59%
Hood River Capital Management LLC2.17%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.14×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend-10.4% → 31.4%

Margin has expanded by about 41.8 points — the business is getting more profitable.

Return on equity40.2%

Latest ROE of 40.2% — capital is generating a healthy return.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $201.3M · EPS 0.50

Est. earnings growth -5.3%

Next fiscal year

Rev $874.7M · EPS 2.25

Est. earnings growth +49.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$605.5M

Net margin

31.4%

ROE

40.2%

Revenue CAGR (2y)

+58.3%

EPS (FY2025)

4.87

Net profit (FY2025)

$190.3M

Ask MarketChacha about TMDX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$605.5M	$190.3M	4.87	31.4%	40.2%
FY2024	$441.5M	$35.5M	1.01	8.0%	15.5%
FY2023	$241.6M	$-25.0M	-0.77	-10.4%	-18.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$189.9M	$14.7M	0.41	7.7%
2026Q1	$173.9M	$7.3M	0.20	4.2%
2025Q3	$143.8M	$24.3M	0.66	16.9%
2025Q2	$157.4M	$34.9M	0.92	22.2%
2025Q1	$143.5M	$25.7M	0.70	17.9%
2024Q3	$108.8M	$4.2M	0.12	3.9%
2024Q2	$114.3M	$12.2M	0.35	10.7%
2024Q1	$96.8M	$12.2M	0.35	12.6%
2023Q3	$66.4M	$-25.4M	-0.78	-38.3%
2023Q2	$52.5M	$-1.0M	-0.03	-1.9%
2023Q1	$41.6M	$-2.6M	-0.08	-6.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC9/10/2026material
8-K — Results of operations, Exhibits
SEC8/4/2026material
10-Q filing
SEC8/4/2026
8-K — Shareholder vote results, Exhibits
SEC5/21/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Results of operations, Exhibits
SEC2/27/2026material
8-K — Results of operations, Exhibits
SEC2/24/2026material
10-K filing
SEC2/24/2026
8-K — Executive/director change
SEC2/4/2026material
8-K — Material agreement, Other events, Exhibits
SEC1/12/2026material

2025

8-K — Results of operations, Exhibits
SEC10/29/2025material
10-Q filing
SEC10/29/2025
8-K — Completion of acquisition/disposition
SEC10/6/2025material
8-K — Results of operations, Exhibits
SEC7/30/2025material
10-Q filing
SEC7/30/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.